Baker's muscular dystrophy is a genetic disorder caused by a genetic defect that primarily affects men and causes flat muscle weakness, particularly in the musculature of the legs and pelvis. This is a disease related to Duchenne muscular dystrophy, both caused by mutations in the same gene. However, Baker muscular dystrophy progresses relatively slowly, and many patients maintain the ability to walk even into their fifties and sixties, making the disease somewhat more acceptable and the patient's quality of life maintained.
The main symptoms of Baker muscular dystrophy include muscle weakness in the legs and pelvis, along with a loss of muscle mass.
In addition, patients may experience calf muscle growth in the age group of five to fifteen years as the body attempts to compensate for the loss of muscle strength, but over time this muscle tissue will eventually be lost to fat. and connective tissue replacement, leading to the so-called pseudohypertrophy phenomenon. Although the condition can also occur in the arms, neck, and other areas, it is less noticeable than in the lower limbs.
Potential complications of Baker muscular dystrophy include cardiac arrhythmias, pulmonary insufficiency, and pneumonia. In addition, this disease is associated with a relatively lower incidence of psychological disorders than Duchenne muscular dystrophy. As the condition changes, a patient's quality of life may be affected, but with appropriate treatment and assistive devices, many patients are still able to maintain a certain level of independence.
Baker muscular dystrophy is caused by mutations or deletions in the DMD gene, which is located on the X chromosome and is inherited in an X-linked recessive manner.
Because women have two X chromosomes, if one is defective, the other usually compensates for the loss, so women rarely show obvious symptoms. For children of carriers, the mother's carrier status affects the risk, with carriers having a 50% chance of passing on the mutation in each pregnancy.
Diagnosing Baker muscular dystrophy usually requires a physical exam to assess muscle development and a muscle biopsy to check for antibodies in the muscle cells. In addition, the creation of biochemical tests and genetic tests to check for mutations in the DMD gene are effective means of gradually confirming the diagnosis of this disease.
Although there is still no cure for Baker muscular dystrophy, some management strategies can reduce symptoms and improve patients' quality of life. Physical therapy, corrective surgery, and the use of assistive devices (such as wheelchairs and braces) are all part of maintaining muscle strength and function. Immunosuppressive drugs such as steroids can slow the progression of the disease.
As scientific research progresses, new treatments, such as gene therapy and other specific drugs, are being developed that are designed to target the root causes of disease.
While the length and quality of life for people with Becker muscular dystrophy varies from person to person, as treatments improve and the understanding of the condition increases, many people live into their fifties and even sixties. However, what we should be thinking about is: How can we better support these patients and their families while pursuing a cure for the disease?